首页> 外文期刊>The Prostate >Effect of a phytotherapeutic agent, Eviprostat(R), on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis.
【24h】

Effect of a phytotherapeutic agent, Eviprostat(R), on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis.

机译:在非细菌性前列腺炎的大鼠模型中,植物治疗剂Eviprostat®对前列腺和尿液细胞因子/趋化因子的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Chronic inflammation in the prostate has recently been recognized as an important component of the symptom progression of benign prostatic hyperplasia. The objective of this study was to evaluate a range of cytokines/chemokines in prostate tissue and urine to identify markers of prostate inflammation in a prostatitis model and to investigate the effect of a phytotherapeutic agent, Eviprostat(R), on these markers. METHODS: Ten-month-old male Wistar rats were divided into four groups. Nonbacterial prostatitis (NBP) was experimentally induced in groups 2-4 by castration followed by daily subcutaneous injection of 17beta-estradiol for 30 days. Control rats were fed a standard diet, while animals in the Eviprostat groups were fed a diet containing 0.05 or 0.1% Eviprostat for 30 days. The levels of cytokines/chemokines in prostate tissue on the 31st day and in urine collected the day before castration and the day before removal of the prostate were determined. RESULTS: Experimentally induced NBP increased the prostatic levels of the cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha). The levels of the chemokines CCL2/monocyte chemoattractant protein-1 (MCP-1), CCL3/macrophage inflammatory protein-1alpha (MIP-1alpha), CXCL1/CINC-1, CXCL3/CINC-2, and CXCL5/LIX were elevated in both prostate and urine. Eviprostat significantly suppressed the increases in prostate IL-1beta, TNF-alpha and CCL3/MIP-1alpha and prostatic and urinary CCL2/MCP-1 and CXCL1/CINC-1. CONCLUSIONS: Chemokines, including CCL2/MCP-1 and CXCL1/CINC-1, were elevated in the prostate and urine of NBP rats, and Eviprostat potently suppressed the increases in CCL2/MCP-1 and CXCL1/CINC-1. These chemokines are therefore candidate diagnostic biomarkers for nonbacterial chronic prostatic inflammation.
机译:背景:前列腺中的慢性炎症最近被认为是良性前列腺增生症状发展的重要组成部分。这项研究的目的是评估前列腺组织和尿液中的一系列细胞因子/趋化因子,以鉴定前列腺炎模型中前列腺炎症的标志物,并研究植物治疗剂Eviprostat®对这些标志物的影响。方法:将十个月大的雄性Wistar大鼠分为四组。通过cast割,然后每天皮下注射17β-雌二醇30天,在实验组2-4中诱导非细菌性前列腺炎(NBP)。对照大鼠接受标准饮食,而依维前列腺素组的动物接受含0.05%或0.1%依维前列腺素的饮食30天。测定第31天在前列腺组织中的细胞因子/趋化因子的水平以及去势前一天和前列腺切除前一天收集的尿液中的细胞因子/趋化因子的水平。结果:实验诱导的NBP增加了细胞因子白介素1β(IL-1beta)和肿瘤坏死因子-α(TNF-alpha)的前列腺水平。趋化因子CCL2 /单核细胞趋化蛋白-1(MCP-1),CCL3 /巨噬细胞炎性蛋白-1alpha(MIP-1alpha),CXCL1 / CINC-1,CXCL3 / CINC-2和CXCL5 / LIX的水平升高前列腺和尿液。 Eviprostat显着抑制前列腺IL-1beta,TNF-alpha和CCL3 / MIP-1alpha以及前列腺和尿液CCL2 / MCP-1和CXCL1 / CINC-1的增加。结论:NBP大鼠的前列腺和尿中的趋化因子(包括CCL2 / MCP-1和CXCL1 / CINC-1)升高,而依维前列腺素有效抑制CCL2 / MCP-1和CXCL1 / CINC-1的升高。因此,这些趋化因子是非细菌性慢性前列腺炎的候选诊断生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号